Discovery of (S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic αvβ6 Integrin Inhibitor for the Inhaled Treatment of Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

Discovery of (S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic αvβ6 Integrin Inhibitor for the Inhaled Treatment of Idiopathic Pulmonary Fibrosis

Published:2018-09-14 Issue:18 Volume:61 Page:8417-8443
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Procopiou Panayiotis A.^ORCID,Anderson Niall A.,Barrett John,Barrett Tim N.,Crawford Matthew H. J.,Fallon Brendan J.,Hancock Ashley P.,Le Joelle,Lemma Seble,Marshall Richard P.,Morrell Josie,Pritchard John M.,Rowedder James E.,Saklatvala Paula,Slack Robert J.,Sollis Steven L.,Suckling Colin J.¹,Thorp Lee R.,Vitulli Giovanni,Macdonald Simon J. F.^ORCID

Affiliation:

1. Department of Pure & Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, Scotland, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00959

Reference61 articles.

1. Idiopathic pulmonary fibrosis: Clinical behavior and aging associated comorbidities

2. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review

3. Idiopathic pulmonary fibrosis